Aurinia Pharmaceuticals Inc (AUPH)

[north40000]

AMRN reportedly looking at an “authorized generic” version of Vascepa, in addition to branded version. Same drug and label, 2 different names and prices(Brand Vascepa for reduction of risk of CVD is $36/year out of pocket for me since mid-2018). Let’s see whether and how generics compete—no entry into market place yet in the Marine market. Generics hope for off label prescriptions and sales into CVD space; Marine market/revenue is relatively small.

Vascepa also has a statutory exclusivity (resulting from FDA approving its sNDA for results in CVDs demonstrated in 8000+ patient Reduce-It trial last 12/2020) that expires 12/2022. It is independent of any RI patents (numbering >40-50 at last count) that expire 2030 and later.

Our LTCG in Amarin far exceeds our LTCG in AUPH(we have 65x more shares of AMRN than 2k AUPH). Basis for AUPH shares = $1.94.